The researchers found that while most glucose-lowering therapies were not significantly associated with a reduction in ...

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced the decision to discontinue development of danuglipron (PF-06882961), an oral glucagon-like peptide-1 (GLP-1) receptor agonist ...

DA-1726 acts as a dual agonist of GLP-1 receptors (GLP1R ... looking statements speak only as of the date when made. MetaVia does not assume any obligation to publicly update or revise any ...

"We look forward to building on United Biotechnology's scientific work and further exploring the potential ... UBT251 is a long-acting synthetic peptide triple agonist targeting the receptors for ...

a triple agonist of the receptors for GLP-1, GIP, and glucagon in early-stage clinical development for the treatment of obesity, type 2 diabetes, and other diseases. Under the license agreement ...

UBT251 is a long-acting synthetic peptide triple agonist targeting the receptors for GLP-1 (glucagon-like peptide-1), GIP (glucose ... This website is not responsible for, and does not control, such ...

a triple agonist of the receptors for GLP-1, GIP, and glucagon in early-stage clinical development for the treatment of obesity, type 2 diabetes, and other diseases. Under the license agreement, Novo ...

“We look forward to building on United Biotechnology’s scientific work and further exploring the potential ... UBT251 is a long-acting synthetic peptide triple agonist targeting the receptors for ...

"We look forward to building on United Biotechnology's scientific work and further exploring ... synthetic peptide triple agonist targeting the receptors for GLP-1 (glucagon-like peptide-1 ...